Document Detail

Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
MedLine Citation:
PMID:  12464588     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Older patients are assumed to have a higher risk of complications from isolated limb perfusion (ILP). A study was performed evaluating the safety and efficacy of ILP in patients older than 75 years with advanced melanoma of the limbs. METHODS: A total of 218 therapeutic ILPs with melphalan with or without tumor necrosis factor alpha were performed in 202 patients with advanced measurable melanoma and were analyzed retrospectively. Fifty-three patients (28%) were 75 years or older. RESULTS: Complete response rates were 56% for those older than 75 years and 58% for the younger group (P =.79). Locoregional relapse occurred in 56% of the older group versus 51% in the younger group (P =.61). Limb toxicity, systemic toxicity, local complications, and long-term morbidity were similar in both age groups. Perioperative mortality was low, with one procedure-related death in the older group. Older patients stayed in the hospital for a median of 23 days (younger patients, 19 days; P <.01). CONCLUSIONS: ILP results in similar response rates in the elderly with recurrent melanoma, without increased toxicity, complications, or long-term morbidity compared with younger patients. Older age in itself is not a contraindication for ILP.
E M Noorda; B C Vrouenraets; O E Nieweg; A N van Geel; A M M Eggermont; B B R Kroon
Related Documents :
18265548 - Is venous reflux a common disease in post-thrombotic patients with unilateral deep vein...
20479258 - End-devonian extinction and a bottleneck in the early evolution of modern jawed vertebr...
9869138 - Muscle transposition flap for salvage of exposed peripheral prosthetic vascular grafts.
18174848 - Long-term outcomes and survival of patients with bilateral transtibial amputations afte...
21726848 - Structural and functional correlation in sickle cell retinopathy using spectral-domain ...
20090478 - Social challenges of cancer patients with orbitofacial disfigurement.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of surgical oncology     Volume:  9     ISSN:  1068-9265     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-04     Completed Date:  2003-03-18     Revised Date:  2007-07-18    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  968-74     Citation Subset:  IM    
Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemotherapy, Cancer, Regional Perfusion / adverse effects,  methods*
Disease-Free Survival
Length of Stay
Linear Models
Melanoma / drug therapy*,  mortality,  pathology
Melphalan / administration & dosage,  adverse effects
Multivariate Analysis
Netherlands / epidemiology
Retrospective Studies
Skin Neoplasms / drug therapy*,  mortality,  pathology
Survival Rate
Tumor Necrosis Factor-alpha / administration & dosage
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Tumor Necrosis Factor-alpha; 148-82-3/Melphalan
Comment In:
Ann Surg Oncol. 2002 Dec;9(10):939-40   [PMID:  12464583 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measu...
Next Document:  Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy...